Setmelanotide

Therapeutic

Indicated for chronic weight management in patients with obesity due to pro-opiomelanocortin deficiency, proprotein subtilisin/kexin type 1 deficiency, or leptin receptor deficiency

Structural features

SMILES

C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5

Sequence

Ac-RCaHfRWC-NH2

Molar mass

1117.32 g/mol

Constitutional members:

8

Natural amino acids

6

D-Amino acids

2

N-terminus

acetyl

C-terminus

NH2

Cyclic

yes

Members/cycle

7

Bond to form cycle

side chain-to-side chain (disulfide)

Lipidation

no

Glycosylation

no

Route of administration

SC

Terminal half-life

Elimination half-life of approximately 11 hours

Protein binding

79.1%

Absorption and Bioavailability

-

References